<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Silibinin, an effective chemo-preventive agent in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, suppresses <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e>, but its effects on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem-like cells (CSLCs) remain unclear </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to examine whether silibinin inhibited the development of CSLCs and disclose the underlying signaling </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> spheroid culture system was used for enriching CSLCs </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of silibinin on CSLCs were evaluated by counting sphere numbers, and calculating the percentage of CD133+ cells by flow cytometry and immunofluorescence both in the absence and presence of different concentrations of silibinin </plain></SENT>
<SENT sid="4" pm="."><plain>The results showed the sphere number of CCS was 36 ± 9.6 after 15 days of CSLC enrichment in spheroid culture, and the percentage of CD133+ cells increased to 18 ± 6.4% compared to 3 ± 0.8% before enrichment </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with silibinin reduced the sphere formation to 5 ± 3.3 and decreased the CD133+ percentage to 8 ± 2.3% </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, treatment of silibinin suppressed the activation of the AKT Ser473/mTOR pathway in spheroid culture through suppressing the activity of protein phosphatase 2Ac subunit (PP2Ac) </plain></SENT>
<SENT sid="7" pm="."><plain>In a xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model, treatment with silibinin also inhibited <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation rate and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Silibinin, which inhibits colon CSLCs self-renewal and sphere formation by suppressing the PP2Ac/AKT Ser473/mTOR pathway, may be a compound for developing new strategies in modulating CSLCs in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>